Investigational antibody targeting two immune checkpoint molecules granted Fast Track Designation by the FDA for the treatment of recurrent and metastatic cervical cancer

AK104, which targets both PD-1 and CTLA-4, is being developed for use as monotherapy for the treatment of patients with recurrent or metastatic squamous cervical cancer who have disease progression on or after platinum-based chemotherapy.


Biospace Inc.